Research study: diffuse large B cell lymphoma
3/10/2014 - 12/31/2014
Frauenshuh Cancer Center
To evaluate the efficacy and safety of Zevalin® and rituximab to standard of care in patients who are in PET-negative complete remission (CR) after first-line R-CHOP or R-CHOP like therapy.
Click here for more information